These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8382876)

  • 1. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients.
    Saliba F; Eyraud D; Samuel D; David MF; Arulnaden JL; Dussaix E; Mathieu D; Bismuth H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1444-5. PubMed ID: 8382876
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis.
    Kizilisik TA; Preiksaitis JK; Kneteman NM
    Transplant Proc; 1993 Jun; 25(3):2282-3. PubMed ID: 8390739
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients].
    Moreno J; Montero JL; Gavilán F; Costán G; Herrero C; Cárdenas M; Sánchez-Guijo P; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 1999 Oct; 17(8):382-5. PubMed ID: 10563084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C; Ducloux D; Ferroni A; Chkoff N; Valette C; Geffrier C; Rouzioux C; Kreis H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871
    [No Abstract]   [Full Text] [Related]  

  • 6. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and gancyclovir.
    Nakazato PZ; Burns W; Moore P; Garcia-Kennedy R; Cox K; Esquivel C
    Transplant Proc; 1993 Apr; 25(2):1935-7. PubMed ID: 7682357
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
    Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir.
    Eisenmann D; Knipp H; Laube H; Stegmann T
    Transplant Proc; 1990 Oct; 22(5):2322-3. PubMed ID: 2171169
    [No Abstract]   [Full Text] [Related]  

  • 11. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S; Ynares C; Dummer S; Helderman JH
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
    Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus disease in liver transplant recipients.
    Jeng LB; Lee WC; Wang CC; Wang KL; Chen SC; Chen MF; Chien RN; Chiu CT; Lin DY; Tan PP
    Transplant Proc; 1994 Aug; 26(4):2227-8. PubMed ID: 8066727
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ; Busuttil RW
    Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients.
    Carrieri G; Jordan ML; Shapiro R; Scantlebury VP; Vivas C; Kusne S; Magnone M; McCauley J; Starzl TE
    Transplant Proc; 1995 Feb; 27(1):961-3. PubMed ID: 7879246
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of cytomegalovirus infection on renal function in kidney transplant recipients.
    Choi SJ; Kim NH; Cho CK; Chung SY; Kim HJ; Choi KC; Kim SK
    Transplant Proc; 1996 Jun; 28(3):1523-4. PubMed ID: 8658769
    [No Abstract]   [Full Text] [Related]  

  • 18. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
    Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
    J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
    Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and therapy of cytomegalovirus disease after liver transplantation.
    Wiens M; Lefèbre B; Blumhardt G; Schmidt CA; Lohmann R; Neuhaus P
    Transplant Proc; 1993 Apr; 25(2):1985-6. PubMed ID: 8385829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.